Diagnosis value of serum B7-H3 expression in non-small cell lung cancer

被引:174
作者
Zhang, Guangbo [1 ,2 ]
Xu, Yuehua [3 ]
Lu, Xudong [4 ]
Huang, Haitao [5 ]
Zhou, Yinghui [6 ]
Lu, Binfeng [7 ]
Zhang, Xueguang [1 ,6 ]
机构
[1] Soochow Univ, Affiliated Hosp 1, Clin Immunol Lab, Suzhou 215007, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Suzhou Key Lab Transplantat Immunol, Suzhou 215007, Peoples R China
[3] Soochow Univ, Affiliated Hosp 2, Dept Respirat, Suzhou 215004, Peoples R China
[4] Soochow Univ, Affiliated Hosp 1, Dept Respirat, Suzhou 215006, Peoples R China
[5] Soochow Univ, Affiliated Hosp 1, Dept Thorac Surg, Suzhou 215006, Peoples R China
[6] Soochow Univ, Inst Med Biotechnol, Suzhou 215007, Peoples R China
[7] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15213 USA
基金
中国国家自然科学基金;
关键词
Soluble B7-H3; Diagnosis; Tumor marker; ELISA; Detection; Non-small cell lung cancer; B7; FAMILY; DENDRITIC CELLS; PROSTATE-CANCER; MOLECULE; MARKER; MEMBER; MOUSE;
D O I
10.1016/j.lungcan.2009.01.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Previous studies have suggested aberrant expression of membrane B7-H3 in tumor cells. This aim of the study was to determine the expression level of soluble B7-H3 (sB7-H3) in circulation and to subsequently evaluate the clinical significance of circulating B7-H3 in patients with non-small cell lung cancer (NSCLC). The level of circulating B7-H3 was determined with ELISA and its correlation with the clinical data was examined. Receiver operating characteristic (ROC) curve analysis was performed to compare the sensitivity and specificity in the diagnosis of NSCLC. Circulating B7-H3 levels in patients with NSCLC were significantly higher than those in patients with other pulmonary diseases (OPD. p < 0.001), or those in healthy volunteers (p < 0.001). Using a cutoff of 30 ng/ml, the sensitivity and specificity of sB7-H3 in differentiating between patients with NSCLC and patients with OPD, and between patients with NSCLC and healthy volunteers was, 48.8 and 98.5%, and 48.0 and 93.7%, respectively. Additionally, higher levels of sB7-H3 were associated with higher tumor stage, tumor size, nodal metastasis, and distant metastasis, but not with sex, age or histological subtype. An area under the curve (AUC) for all stages of NSCLC resulting from sB7-H3 (0.862), which was significantly better than any other tumor markers tested including CA125 (0.621), CA153 (0.571), CA199 (0.459), and CEA (0.638). These results suggest circulating B7-H3 is a valuable biomarker for NSCLC and an elevated level of circulating B7-H3 suggests a poor clinical character for NSCLC. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:245 / 249
页数:5
相关论文
共 25 条
[1]
Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions [J].
Alatas, F ;
Alatas, Ö ;
Metintas, M ;
Çolak, Ö ;
Harmanci, E ;
Demir, S .
LUNG CANCER, 2001, 31 (01) :9-16
[2]
B7-H3:: A costimulatory molecule for T cell activation and IFN-γ production [J].
Chapoval, AI ;
Ni, J ;
Lau, JS ;
Wilcox, RA ;
Flies, DB ;
Liu, D ;
Dong, HD ;
Sica, GL ;
Zhu, GF ;
Tamada, K ;
Chen, LP .
NATURE IMMUNOLOGY, 2001, 2 (03) :269-274
[3]
The B7 family revisited [J].
Greenwald, RJ ;
Freeman, GJ ;
Sharpe, AH .
ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 :515-548
[4]
Cancer statistics, 2005 [J].
Jemal, A ;
Murray, T ;
Ward, E ;
Samuels, A ;
Tiwari, RC ;
Ghafoor, A ;
Feuer, EJ ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (01) :10-30
[5]
SERUM CA125 LEVEL IS A GOOD PROGNOSTIC INDICATOR IN LUNG-CANCER [J].
KIMURA, Y ;
FUJII, T ;
HAMAMOTO, K ;
MIYAGAWA, N ;
KATAOKA, M ;
IIO, A .
BRITISH JOURNAL OF CANCER, 1990, 62 (04) :676-678
[6]
B7-h1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression [J].
Konishi, J ;
Yamazaki, K ;
Azuma, M ;
Kinoshita, I ;
Dosaka-Akita, H ;
Nishimura, M .
CLINICAL CANCER RESEARCH, 2004, 10 (15) :5094-5100
[7]
Cancer statistics, 1999 [J].
Landis, SH ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 1999, 49 (01) :8-31
[8]
Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss [J].
Ling, V ;
Wu, PW ;
Spaulding, V ;
Kieleczawa, J ;
Luxenberg, D ;
Carreno, BM ;
Collins, M .
GENOMICS, 2003, 82 (03) :365-377
[9]
B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells [J].
Luo, LQ ;
Chapoval, AI ;
Flies, DB ;
Zhu, GF ;
Hirano, F ;
Wang, SD ;
Lau, JS ;
Dong, HD ;
Tamada, K ;
Flies, AS ;
Liu, Y ;
Chen, LP .
JOURNAL OF IMMUNOLOGY, 2004, 173 (09) :5445-5450
[10]
An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo [J].
Lupu, Catalin M. ;
Eisenbach, Christoph ;
Kuefner, Michael A. ;
Schmidt, Jan ;
Lupu, Alaviana D. ;
Stremmel, Wolfgang ;
Encke, Jens .
JOURNAL OF GASTROINTESTINAL SURGERY, 2006, 10 (05) :635-645